论文部分内容阅读
目的观察吉西他滨联合卡培他滨(GX方案)治疗术后复发的乳腺癌患者的疗效和不良反应。方法 50例患者分别接受GX方案化疗3～6个周期,按世界卫生组织(WHO)标准评价疗效及不良反应。结果 50例患者均可评价,其中完全缓解(CR)4例(8.0%),部分缓解(PR)22例(44.0%),稳定(SD)18例(36.0%),进展(PD)6例(12.0%)。中位肿瘤进展时间(mTTP)为8.3个月(95%CI:6.55～10.89),中位总生存时间(mOS)为18.0个月(95%CI:14.34～21.98)。主要不良反应为骨髓抑制和皮疹。结论 GX方案治疗晚期乳腺癌安全有效,不良反应较轻,值得临床推广应用。
Objective To observe the efficacy and side effects of gemcitabine combined with capecitabine (GX) in the treatment of postoperative recurrence of breast cancer. Methods Fifty patients were treated with GX regimen for 3 ~ 6 cycles respectively. The curative effect and adverse reactions were evaluated according to the World Health Organization (WHO) criteria. Results All of the 50 patients were eligible for evaluation. Among them, 4 were CR (8.0%), 22 (44.0%) were PR, 18 (36.0%) were stable and 6 were PD (12.0%). The median time to tumor progression (mTTP) was 8.3 months (95% CI: 6.55 to 10.89) and median overall survival time (mOS) was 18.0 months (95% CI: 14.34 to 21.98). The main adverse reactions were myelosuppression and rash. Conclusion GX regimen is safe and effective in the treatment of advanced breast cancer with mild adverse reactions. It is worthy of clinical application.